Astellas’ generic Myrbetriq defence knocked back again

Low-cost competition in the US to Astellas’ Myrbetriq for urinary incontinence has arrived after a court recommended denying an injunction on the launch of generics.

Astellas hit by US patent verdict for incontinence drug

A US district court has said that a key patent held by Astellas on its Myrbetriq drug for urinary incontinence is invalid, in a setback to its efforts to defend the blockb

NICE backs Axonics’ rechargeable device for overactive bladd...

Wireless neurostimulator for overactive bladder given CE mar...

Device is roughly 90% smaller than currently available neurostimulators.